Use Of Riluzole Prodrugs To Treat Ataxias
Patent No. EP3706739 (titled "Use Of Riluzole Prodrugs To Treat Ataxias") was filed by Biohaven Pharmaceutical Holding on Nov 11, 2018. The application was issued on Oct 16, 2024.
Patent Summary
Prodrugs of riluzole for treating spinocerebellar ataxia (SCA) comprising a riluzole molecule linked to a hydrophilic moiety, such as a carboxylic acid or ester group, to enhance solubility and bioavailability. The prodrugs are administered orally in a dosage of 17.5-200 mg/day, with a preferred dosage of 100-140 mg/day, and are effective in improving symptoms of SCA, including ataxia, dysarthria, and dysphagia, as measured by clinical rating scales such as the Scale for the Assessment and Rating of Ataxia (SARA).
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3706739
- Application Number
- EP18876779A
- Filing Date
- Nov 11, 2018
- Status
- Granted And Under Opposition
- Sep 13, 2024
- Publication Date
- Oct 16, 2024
- External Links
- Slate, Register , Google Patents